keyword
MENU ▼
Read by QxMD icon Read
search

Therapie

keyword
https://www.readbyqxmd.com/read/29055288/osteoinductive-effects-of-cyplexinol-in-the-management-of-osteoporosis-a-case-series
#1
Daniel Tripodi
Aims • A case study was conducted on a subject with a history of documented bone loss and the observed outcome of bone mineral density (BMD) changes when utilizing supplementation with Cyplexinol, a natural bone morphogenetic protein complex. Method and Results • A case of osteoporosis was reviewed with pertinent medical history and dual energy X-ray absorptiometry history described both pre- and postsupplementation. Results demonstrated a significant change in bone density parameter for the individual when the bone support supplement, Cyplexinol, was used...
October 21, 2017: Alternative Therapies in Health and Medicine
https://www.readbyqxmd.com/read/29055286/in-defense-of-progesterone-a-review-of-the-literature
#2
Allan Lieberman, Luke Curtis
Context • The medical literature on the use of progesterone in postmenopausal women is often confusing and contradictory. Some physicians implicate natural progesterone in an increase in the risk of breast cancer. The chemical structure of natural progesterone (P4) is quite different from chemically altered, synthetic chemicals called progestins, which results in different actions at the cell level. Objective • The research team intended to review the literature to examine the benefits and safety of natural progesterone and determine whether it can cause an increase or decrease in breast cancer risk...
October 21, 2017: Alternative Therapies in Health and Medicine
https://www.readbyqxmd.com/read/29055248/simultaneous-quantification-of-direct-oral-anticoagulants-currently-used-in-anticoagulation-therapy
#3
Kathrin I Foerster, Andrea Huppertz, Oliver J Müller, Timolaos Rizos, Lisa Tilemann, Walter E Haefeli, Jürgen Burhenne
Direct oral anticoagulants (DOACs) are among the most effective options to prevent serious thromboembolic events in patients with atrial fibrillation. Coagulation assays are used to assess DOAC activity, but lack the possibility to quantify drugs with concurrent pharmacodynamic effect. We developed a selective multi-drug assay to analyze apixaban, betrixaban, dabigatran, edoxaban, edoxaban M4, and rivaroxaban with ultra-performance liquid chromatography coupled to tandem mass spectrometry (UPLC/MS/MS) in plasma fulfilling all requirements of the FDA und EMA guidelines for bioanalytical method validation...
October 16, 2017: Journal of Pharmaceutical and Biomedical Analysis
https://www.readbyqxmd.com/read/29055231/correcting-cftr-folding-defects-by-small-molecule-correctors-to-cure-cystic-fibrosis
#4
REVIEW
Marjolein Mijnders, Bertrand Kleizen, Ineke Braakman
Pharmacological intervention to treat the lethal genetic disease cystic fibrosis has become reality, even for the severe, most common folding mutant F508del CFTR. CFTR defects range from absence of the protein, misfolding that leads to degradation rather than cell-surface localization (such as F508del), to functional chloride-channel defects on the cell surface. Corrector and potentiator drugs improve cell-surface location and channel activity, respectively, and combination therapy of two correctors and a potentiator have shown synergy...
October 18, 2017: Current Opinion in Pharmacology
https://www.readbyqxmd.com/read/29055218/cyp2c9-and-vkorc1-in-therapeutic-dosing-and-safety-of-acenocoumarol-treatment-implication-for-clinical-practice-in-hungary
#5
Reka Varnai, Csilla Sipeky, Lajos Nagy, Sandor Balogh, Bela Melegh
The purpose of this work was to investigate the contribution of CYP2C9 and VKORC1 to acenocoumarol (AC) dose variability, bleeding events in Hungary. The study recruited 117 patients on long-term AC therapy (INR 2-3), and 510 healthy individuals to model the findings. Patients were genotyped for alleles proved to affect lower AC overdose CYP2C9*2, CYP2C9*3, VKORC1*2. Additionally, we tested VKORC1*3, VKORC1*4 to examine their effect in patients with higher AC requirements. Most impact on dose reduction is accountable for CYP2C9*2/*3 (59%) and for VKORC1*2/*2 (45...
October 8, 2017: Environmental Toxicology and Pharmacology
https://www.readbyqxmd.com/read/29055216/thoracic-manual-therapy-is-not-more-effective-than-placebo-thoracic-manual-therapy-in-patients-with-shoulder-dysfunctions-a-systematic-review-with-meta-analysis
#6
REVIEW
Paolo Bizzarri, Luca Buzzatti, Erik Cattrysse, Aldo Scafoglieri
BACKGROUND: Manual treatments targeting different regions (shoulder, cervical spine, thoracic spine, ribs) have been studied to deal with patients complaining of shoulder pain. Thoracic manual treatments seem able to produce beneficial effects on this group of patients. However, it is not clear whether the patient improvement is a consequence of thoracic manual therapy or a placebo effect. OBJECTIVES: To compare the efficacy of thoracic manual therapy and placebo thoracic manual treatment for patients with shoulder dysfunction...
October 14, 2017: Musculoskeletal Science & Practice
https://www.readbyqxmd.com/read/29055182/computational-drug-repositioning-for-rare-diseases-in-the-era-of-precision-medicine
#7
REVIEW
Brian Delavan, Ruth Roberts, Ruili Huang, Wenjun Bao, Weida Tong, Zhichao Liu
There are tremendous unmet needs in drug development for rare diseases. Computational drug repositioning is a promising approach and has been successfully applied to the development of treatments for diseases. However, how to utilize this knowledge and effectively conduct and implement computational drug repositioning approaches for rare disease therapies is still an open issue. Here, we focus on the means of utilizing accumulated genomic data for accelerating and facilitating drug repositioning for rare diseases...
October 18, 2017: Drug Discovery Today
https://www.readbyqxmd.com/read/29055181/pfa-100-measured-aspirin-resistance-is-the-predominant-risk-factor-for-hospitalized-cardiovascular-events-in-aspirin-treated-patients-a-5-year-cohort-study
#8
H Y Chen, P Chou
WHAT IS KNOWN AND OBJECTIVE: Aspirin therapy is the clinical gold standard for the prevention of cardiovascular events. However, cardiovascular events still develop in some patients undergoing aspirin therapy. Many laboratory methods exist for measuring aspirin resistance. Using the platelet Function Analyzer (PFA)-100 system, we aimed to determine the effect of aspirin resistance on hospitalized cardiovascular events (hCVE) in a 5-year follow-up cohort. We also sought to determine the impact of aspirin resistance on the relationship between common cardiovascular risk factors and cardiovascular hospitalization...
October 21, 2017: Journal of Clinical Pharmacy and Therapeutics
https://www.readbyqxmd.com/read/29055173/safety-and-efficacy-of-the-cervical-pessary-combined-with-vaginal-progesterone-for-the-prevention-of-spontaneous-preterm-birth
#9
Georgios Daskalakis, Dimitrios Zacharakis, Marianna Theodora, Panagiotis Antsaklis, Nikolaos Papantoniou, Dimitris Loutradis, Aris Antsaklis
INTRODUCTION: The aim of this study was to evaluate the safety and efficacy of the combined treatment of cervical pessary and endovaginal progesterone for the prevention of spontaneous preterm birth (SPB) in women with a short cervical length (CL) between 20 and 24 weeks of gestation. MATERIALS AND METHODS: This is a prospective study of women with a singleton pregnancy and a sonographically detected mid-trimester CL ≤25 mm. The primary outcome measure was spontaneous delivery before 34 weeks (238 days) of gestation...
October 21, 2017: Journal of Perinatal Medicine
https://www.readbyqxmd.com/read/29055168/long-term-safety-of-growth-hormone-a-combined-registry-analysis
#10
Kirstine Stochholm, Wieland Kiess
OBJECTIVES: Preliminary data from the French cohort of the Safety and Appropriateness of Growth hormone treatments in Europe (SAGhE) study raised concerns regarding the safety of recombinant human GH, suggesting that GH may increase mortality and incidence of stroke in patients treated during childhood for GH deficiency or short stature. We evaluated published safety data, focusing on mortality, neoplasms, cerebrovascular events and diabetes across a number of large-scale pharmaceutical company GH registries...
October 21, 2017: Clinical Endocrinology
https://www.readbyqxmd.com/read/29055166/drug-monitoring-of-sunitinib-in-patients-with-advanced-solid-tumors-a-monocentric-observational-french-study
#11
Luc Cabel, Benoit Blanchet, Audrey Thomas-Schoemann, Olivier Huillard, Audrey Bellesoeur, Anatole Cessot, Julie Giroux, Pascaline Boudou-Rouquette, Romain Coriat, Michel Vidal, Nathaniel E B Saidu, Lisa Golmard, Jérome Alexandre, Francois Goldwasser
Therapeutic drug monitoring (TDM) could be helpful in oral targeted therapies. Data are sparse to evaluate its impact on treatment management. This study aimed to determine a threshold value of plasma drug exposure associated with the occurrence of grade 3-4 toxicity, then the potential impact of TDM on clinical decision. Consecutive outpatients treated with sunitinib were prospectively monitored between days 21-28 of the first cycle, then monthly until disease progression. At each consultation, the composite AUCƬ,ss (sunitinib + active metabolite SU12662) was assayed...
October 21, 2017: Fundamental & Clinical Pharmacology
https://www.readbyqxmd.com/read/29055165/development-of-tripe-palms-and-soles-in-a-patient-with-long-pre-existing-systemic-mastocytosis-and-newly-developed-non-small-cell-lung-cancer
#12
Hanna Bonnekoh, Tatevik Ohanyan, Dido Lenze, Karoline Krause, Marcus Maurer, Torsten Zuberbier, Frank Siebenhaar
A 71-year old woman with systemic mastocytosis presented to our department with an apoplectic insult one year ago and a 100 pack year smoking history. Skin manifestation of mastocytosis had started at the age of 50 years accompanied by a substantial increase of serum tryptase since the age of 60. Bone marrow involvement was confirmed 16 years later. Therapy of mastocytosis included antihistamines, montelukast, sodium cromoglycate, and PUVA therapy, all with limited success. This article is protected by copyright...
October 21, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/29055143/pasireotide-for-the-treatment-of-refractory-hypoglycemia-from-malignant-insulinoma
#13
Nicholas S Hendren, Kamaldeep Panach, Timothy J Brown, Lan Peng, Muhammad S Beg, Jonathan Weissler, Sasan Mirfakhraee
Insulinomas are rare, usually solitary benign tumors. The presence of metastases defines malignant insulinomas((1)) . Medical therapy primarily treats symptomatic hypoglycemia, alleviates symptoms, and improves the quality of life in affected individuals. While diazoxide is used as first-line therapy, the incomplete response rate and complications associated with diazoxide provide a role for somatostatin analogues in difficult-to-treat hypoglycemia. This article is protected by copyright. All rights reserved...
October 21, 2017: Clinical Endocrinology
https://www.readbyqxmd.com/read/29055137/reply-to-topical-ionic-contra-viral-therapy-comprised-of-digoxin-and-furosemide-as-a-potential-novel-treatment-approach-for-common-warts
#14
Ayman Abdelmaksoud
I read with great interest a preliminary study on new treatment for common warts conducted by Kolk et al.(1) The authors studied, for the first time, the clinical response of common warts to topical application of a fixed dose of 980 mg topical gel containing 0.125% (w/w) digoxin and 0.125% (w/w) furosemide for 7 consecutive days on the patients' lower back. Basically, topical therapy for a common dermatosis is generally welcomed particularly if showed a higher degree of safety profile and less potential off-target adverse effects...
October 21, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/29055135/treatment-of-prurigo-with-methotrexate-a-multicenter-retrospective-study-of-39-cases-running-head-treatment-of-prurigo-with-methotrexate
#15
T Klejtman, M Beylot-Barry, P Joly, M A Richard, S Debarbieux, L Misery, P Wolkenstein, O Chosidow, S Ingen-Housz-Oro
BACKGROUND: Prurigo is a common primary pruritic condition. Treatment is challenging. Methotrexate (MTX) is effective for the treatment of pruriginous dermatoses, but its use in prurigo has been little studied. OBJECTIVES: To investigate the efficacy and safety of MTX in the treatment of difficult-to-treat prurigo. METHODS: Patients from six university dermatology departments treated with MTX between 2006 and 2016 for difficult-to-treat prurigo (i...
October 21, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/29055132/gram-negative-bacterial-toe-web-infection-a-systematic-review
#16
REVIEW
Till Weidner, Jörg Tittelbach, Tanja Illing, Peter Elsner
Gram-negative bacterial toe web infection (GNBTWI) is a frequent therapeutic challenge in clinical practice with high recurrence rates and frequent need of systemic drugs. The aim of this systematic review was to provide an updated overview and evidence-based data on pathogens, risk-factors and treatment of GNBTWI along with promoting a consistent international terminology. This systematic review is based on a search in PubMed database for English and German articles published between 1980 and 2016. A total of 7 articles were considered appropriate for inclusion in this review regarding to treatment and outcome...
October 21, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/29055130/randomized-trial-of-combined-cabergoline-and-coasting-in-preventing-ovarian-hyperstimulation-syndrome-during-in-vitro-fertilization-intracytoplasmic-sperm-injection-cycles
#17
Yasmin A Bassiouny, Dina M R Dakhly, Yomna A Bayoumi, Noha M Salaheldin, Hisham M Gouda, Ayman A Hassan
OBJECTIVE: To assess the efficacy of coasting alone, cabergoline alone, or combining both interventions for preventing ovarian hyperstimulation syndrome (OHSS) among high-risk patients undergoing in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) treatment cycles. METHODS: The present randomized controlled trial was conducted at the IVF unit of a university hospital in Cairo between October 28, 2013, and July 31, 2015. Patients undergoing IVF/ICSI considered at risk of OHSS were randomly allocated to coasting, cabergoline, or combined coasting and cabergoline...
October 21, 2017: International Journal of Gynaecology and Obstetrics
https://www.readbyqxmd.com/read/29055129/desmopressin-for-treating-nocturia-in-men
#18
REVIEW
Julia Han, Jae Hung Jung, Caitlin J Bakker, Mark H Ebell, Philipp Dahm
BACKGROUND: Nocturia is the bothersome symptom of awakening one or more times per night to void. Desmopressin is a commonly used medication for treating nocturia. OBJECTIVES: To assess the effects of desmopressin as compared to other interventions in the treatment of nocturia in men. SEARCH METHODS: We performed a comprehensive search of medical literature with no restrictions on the language of publication or publication status. The date of the latest search of all databases was August 2017...
October 21, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29055125/vascular-endothelial-growth-factor-vegf-related-single-nucleotide-polymorphisms-rs10738760-and-rs6921438-are-not-associated-with-diabetic-retinopathy-dr-in-slovenian-patients-with-type-2-diabetes-mellitus-t2dm
#19
Rifet Terzić, Ines Cilenšek, Ruda Zorc Pleskovič, Sara Mankoč, Aleksandra Milutinović
Diabetic retinopathy (DR) is a complication of diabetes characterized by vascular permeability, increased tissue ischemia, and angiogenesis. One of the most important proteins involved in angiogenesis is vascular endothelial growth factor (VEGF, also known as VEGFA). A previous study demonstrated that two single nucleotide polymorphisms (SNPs), rs6921438 and rs10738760, account for nearly half the variation in circulating VEGF levels. The aim of our study was to assess the association between rs6921438 and rs10738760 and DR in Slovenian patients with type 2 diabetes mellitus (T2DM)...
October 20, 2017: Bosnian Journal of Basic Medical Sciences
https://www.readbyqxmd.com/read/29055113/accelerating-patient-access-to-novel-biologics-using-stable-pool-derived-product-for-non-clinical-studies-and-single-clone-derived-product-for-clinical-studies
#20
Trent P Munro, Kim Le, Huong Le, Li Zhang, Jennitte Stevens, Neil Soice, Sabrina A Benchaar, Robert W Hong, Chetan T Goudar
Cell cloning and subsequent process development activities are on the critical path directly impacting the timeline for advancement of next generation therapies to patients with unmet medical needs. The use of stable cell pools for early stage material generation and process development activities is an enabling technology to reduce timelines. To successfully use stable pools during development, it is important that bioprocess performance and requisite product quality attributes be comparable to those observed from clonally derived cell lines...
October 21, 2017: Biotechnology Progress
keyword
keyword
43850
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"